A event on Wednesday 6th May. The event starts at 19:30.
As MDMA and psilocybin edge closer towards being approved as medicines, we are seeing a split emerge in the psychedelic community, with some people favouring medical approval and others becoming increasingly fearful of pharmaceutical companies moving into the psychedelic space. Dr Sessa will discuss this issue in the context of 15 years of carrying out psychedelic research.
Talk Starts: 7:30pm
Tickets: http://hdfst.uk/E62425
In the last ten years, Dr. Ben Sessa has worked on several UK-based human pharmacology trials as a study doctor or as a healthy subject administering and receiving test doses of LSD, DMT, psilocybin, MDMA, and ketamine. He is the author of several dozen peer-reviewed articles in the mainstream medical press and has written two books exploring psychedelic medicine; The Psychedelic Renaissance (2012 / 2017) and To Fathom Hell or Soar Angelic (2015). In speaking publicly at universities and medical conferences, Dr. Sessa is outspoken on lobbying for change in the current system by which drugs are classified in the UK, believing a more progressive policy of regulation would reduce the harms of recreational drug use and provide increased opportunities for clinical psychedelic research.
He is also a co-founder and director of the UK's Breaking Convention conference. www.drsessa.com
Entry requirements:
Talk Starts: 7:30pm
Tickets: http://hdfst.uk/E62425
In the last ten years, Dr. Ben Sessa has worked on several UK-based human pharmacology trials as a study doctor or as a healthy subject administering and receiving test doses of LSD, DMT, psilocybin, MDMA, and ketamine. He is the author of several dozen peer-reviewed articles in the mainstream medical press and has written two books exploring psychedelic medicine; The Psychedelic Renaissance (2012 / 2017) and To Fathom Hell or Soar Angelic (2015). In speaking publicly at universities and medical conferences, Dr. Sessa is outspoken on lobbying for change in the current system by which drugs are classified in the UK, believing a more progressive policy of regulation would reduce the harms of recreational drug use and provide increased opportunities for clinical psychedelic research.
He is also a co-founder and director of the UK's Breaking Convention conference. www.drsessa.com
Entry requirements:
Tickets for similar Bristol events.
